<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0"><channel><title>Individual feed for https://medicalxpress.com/rss-feed/</title><link>https://medicalxpress.com/rss-feed/</link><description>Individual feed output.</description><lastBuildDate>Mon, 08 Dec 2025 07:22:05 GMT</lastBuildDate><generator>PyRSS2Gen-1.1.0</generator><docs>http://blogs.law.harvard.edu/tech/rss</docs><item><title>Aza–ven combination outperforms standard care in AML patients eligible for intensive chemotherapy</title><link>https://medicalxpress.com/news/2025-12-azaven-combination-outperforms-standard-aml.html</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture7.png</image_url><description>In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen of azacitidine and venet...</description><pubDate>Mon, 08 Dec 2025 11:37:23 GMT</pubDate></item><item><title>New findings support a chemo-free approach for treating Ph+ ALL</title><link>https://medicalxpress.com/news/2025-12-chemo-free-approach-ph.html</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture10.png</image_url><description>A chemotherapy-free combination treatment outperformed a combination of targeted therapy and chemotherapy among patients with Ph+ acute lymphoblastic ...</description><pubDate>Mon, 08 Dec 2025 11:36:34 GMT</pubDate></item><item><title>Adding epcoritamab to standard second-line therapy improves follicular lymphoma outcomes</title><link>https://medicalxpress.com/news/2025-12-adding-epcoritamab-standard-line-therapy.html</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture2.png</image_url><description>In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction in the risk of death or ...</description><pubDate>Mon, 08 Dec 2025 11:35:22 GMT</pubDate></item><item><title>Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL</title><link>https://medicalxpress.com/news/2025-12-covalent-btki-pirtobrutinib-frontline-therapy.html</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture8.png</image_url><description>Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate i...</description><pubDate>Mon, 08 Dec 2025 11:34:35 GMT</pubDate></item><item><title>Roughly one-third of families with children being treated for leukemia struggle to pay living expenses</title><link>https://medicalxpress.com/news/2025-12-roughly-families-children-leukemia-struggle.html</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture3.png</image_url><description>Nearly a third of families with children receiving chemotherapy for acute lymphoblastic leukemia (ALL)—the most common pediatric cancer—develop seriou...</description><pubDate>Mon, 08 Dec 2025 11:33:37 GMT</pubDate></item></channel></rss>